DR4 — Hydroxamic Acid + 2-Amino-Quinoline-3 Chemotype IP Landscape and Hidden Toxicity Liabilities

DR4 — Hydroxamic Acid + 2-Amino-Quinoline-3 Chemotype: IP Landscape and Hidden Toxicity Liabilities

Executive Summary

The lead pharmacochaperone candidate under investigation is structurally defined by a 2-amino-quinoline-3-carboxylic acid core wherein the carboxylate is replaced by a hydroxamic acid (–C(=O)NHOH) zinc-binding group (ZBG), coupled with a bulky adamantyl-amine tail at the C2 position, and an R-substituent on the quinoline ring. The designated clinical indication is the treatment of autosomal recessive hearing loss (DFNB16), caused by mutations in the STRC (stereocilin) gene, via oral or intratympanic delivery in pediatric cohorts globally. The dual structural elements—the hydroxamic acid head and the 2-amino-quinoline scaffold—pose multifaceted intellectual property (IP) challenges and carry severe, well-documented toxicity liabilities.

This exhaustive research report evaluates the patent landscape to assess freedom to operate (FTO), identifies critical toxicological pathways associated with the hydroxamic acid, 2-amino-quinoline, and adamantyl chemotypes across clinical and preclinical stages, and delivers an actionable preclinical wet-lab screening plan tailored to both intratympanic and systemic delivery routes.

Part A — Intellectual Property Landscape

The assessment of the IP landscape surrounding the 2-amino-quinoline-3-hydroxamate class requires evaluating core scaffold patents, adamantyl-amine substitution methodologies, the application of hydroxamic acids in non-HDAC contexts, the scope of pharmacochaperone concept patents, and emerging small-molecule strategies for inner-ear genetic disorders.

1. Patents Covering 2-Amino-Quinoline-3 Carboxamides / Hydroxamates

The foundational patent covering 2-amino-quinoline-3-carboxylic acid derivatives was established by Eastman Kodak Co. under US Patent No. 3,446,809A, with a priority date of January 1966. This patent, which expired in 1986, placed the fundamental unadorned 2-amino-quinoline-3-carboxamide and its immediate synthetic derivatives into the public domain. However, modern pharmaceutical FTO depends heavily on the specific claim language and Markush group limitations applied in contemporary patents. [1][2][3]

Under jurisdictional case law, particularly in the United States (e.g., Shire Development, LLC v. Watson Pharmaceuticals, Inc.) and Canada (e.g., Abbott Laboratories v Canada), the recitation of a Markush group utilizing the closed transitional phrase “consisting of” rigorously limits the scope to the expressly named substituents. Consequently, any prior art claiming “a zinc-binding group selected from the group consisting of carboxylate, tetrazole, and amide” inherently fails to capture a hydroxamic acid modification unless explicitly recited. Furthermore, while recent synthetic patents describe the cyclization of 2-aminoquinoline-3-carboxamides into complex pyrimido-quinolines, these patents cover discrete cyclized end-products rather than the linear hydroxamic acid scaffold. Our extensive review indicates that the specific linear 2-amino-quinoline-3-hydroxamate core, unencumbered by additional ring fusions, exists within a highly favorable FTO space, provided the combination of R-substituents and the C2-adamantyl tail is entirely novel. [1][2][3]

2. Adamantyl-Amine-Aryl Medicinal Chemistry Patents

The attachment of an adamantyl tail via an amine linkage to a heteroaromatic core is a heavily utilized strategy in medicinal chemistry, historically anchoring the memantine and amantadine drug classes. Current patent space reveals broad synthetic claims capturing adamantyl-amine functionalization. For instance, European Patent EP2949655B1 (granted to Novartis AG for direct amination processes) details the reaction of halogenated heteroaryls with aliphatic primary amines, explicitly citing both “adamantyl amine” and “2-aminoquinoline” within the specification. Similarly, US Patent No. 8,680,139B2 outlines the synthesis of N-((1r,3r,5r,7r)-adamantan-2-yl) carboxamides linked to nitrothiophene and other aromatic rings. [1][2][3]

While these patents claim specific synthetic processes or structurally distinct cores (e.g., thiophenes, pyrimidines, or specifically functionalized indanones), the precise combination of a 2-amino-quinoline substituted at the C2 position with an adamantyl-amine is largely devoid of active composition-of-matter claims in the context of hearing loss. The adamantyl moiety is frequently deployed as a lipophilic anchor; thus, while the fragment itself is ubiquitous, its specific spatial presentation on the C2 position of a quinoline-3-hydroxamate represents free intellectual property space. [1][2][3]

3. Hydroxamic Acid Drug Patents in Non-HDAC Indications

Hydroxamic acids are ubiquitous in the patent literature due to their unmatched efficiency as bidentate zinc and iron chelators. While primarily claimed in HDAC inhibitors, they are also heavily patented in matrix metalloproteinase (MMP) and UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors. [1][2][3]

The LpxC inhibitor space is crowded with hydroxamate patents, notably from Achaogen (covering the failed clinical candidate ACHN-975) and Pfizer (covering PF-5081090). However, these patents consistently define the scaffold using a methylsulfone, isoserine, or arazoline core. Because the Markush boundaries of these estates strictly require these aliphatic or monocyclic backbones, they fail to read onto a fused bicyclic quinoline core. Similarly, MMP inhibitor patents (e.g., those covering marimastat or batimastat) require succinyl or complex peptidomimetic backbones. As such, the non-HDAC hydroxamate prior art clusters far away from the rigid, aromatic 2-amino-quinoline geometry. [1][2][3]

4. Pharmacochaperone and Fold-Rescue Patents

The concept of using small molecules to stabilize misfolded proteins (pharmacochaperones) has been pioneered by companies such as FoldRx (acquired by Pfizer, covering tafamidis for transthyretin amyloidosis), Amicus Therapeutics (covering migalastat for alpha-galactosidase A in Fabry disease), and Vertex Pharmaceuticals (covering CFTR correctors for cystic fibrosis).

A critical analysis of these patent families reveals that they do not possess broad, conceptual claims covering the general mechanism of small-molecule fold-stabilization of any extracellular glycoprotein. Instead, their claims are rigorously restricted to their specific target proteins and highly specific chemical scaffolds (e.g., the benzoxazole core of tafamidis or the iminosugar core of migalastat). Therefore, applying a novel quinoline-based small molecule as a pharmacochaperone for stereocilin (the STRC gene product responsible for DFNB16) faces zero FTO risk from the legacy pharmacochaperone patent estates.

5. Hearing-Loss Small-Molecule Patents (2014–2026)

The therapeutic landscape for DFNB16 and general sensorineural hearing loss (SNHL) is currently dominated by gene therapy protocols, leaving a massive “white space” for small-molecule interventions.

Patent FTO Risk Inventory

Chemotype / Concept	Representative Prior Art / Assignee	FTO Risk Level	Legal Reasoning & Structural Distinctions
2-Amino-quinoline-3-carboxamides	US3446809A (Eastman Kodak Co.)	Low	Patent expired in 1986. The foundational linear scaffold is in the public domain.
Adamantyl-amine linkage to heteroaryls	EP2949655B1 (Novartis); US8680139B2	Low	Existing patents claim specific heteroaryl cores (e.g., thiophene) or specific amination processes. No active composition-of-matter claims capture a C2-adamantyl-amine on a 2-amino-quinoline core.
Non-HDAC Hydroxamates (LpxC / MMP)	Achaogen LpxC Estate; Pfizer LpxC Estate	Low	Scaffold Markush boundaries rely on methylsulfone, isoserine, or succinyl backbones. A quinoline core falls entirely outside these restrictions.
	Pharmacochaperone Mechanism	Pfizer (FoldRx); Amicus; Vertex	Low
DFNB16 Therapeutics	Decibel Therapeutics / Regeneron	Low	Decibel’s STRC-directed IP relies exclusively on AAV-mediated cDNA transfer (gene therapy).
Intratympanic Small Molecules for SNHL	Frequency Therapeutics (FX-322)	Medium	Frequency holds patents covering the intratympanic delivery of HDAC inhibitors combined with Wnt activators. Our lead contains a hydroxamate, which naturally inhibits HDACs. FTO requires ensuring our method-of-use claims are framed strictly around STRC fold-rescue rather than regenerative HDAC inhibition.

Part B — Hydroxamic-Acid Class Toxicity

The presence of the hydroxamic acid (–C(=O)NHOH) functional group dictates the dominant safety liabilities of this chemotype. As an exceptional bidentate zinc and iron chelator, the moiety interacts promiscuously with mammalian metalloenzymes, leading to widespread clinical failures. The safety profile is heavily dependent on systemic exposure versus local (intratympanic) compartmentalization.

1. Approved Hydroxamic-Acid Drugs and FDA Label Signals

The FDA has approved several hydroxamic-acid derivatives, primarily as histone deacetylase (HDAC) inhibitors for oncology. The adverse event (AE) profiles of these agents define the inherent baseline toxicity of the pharmacophore.

Pediatric Exposure Data:

Hydroxamic acid toxicities are not isolated to adults. Givinostat (Duvyzat), a recently approved hydroxamate-based HDAC inhibitor for Duchenne Muscular Dystrophy, provides critical pediatric exposure data for patients aged 6 and older. In pediatric cohorts, the drug similarly causes dose-limiting thrombocytopenia, severe diarrhea, vomiting, and QTc prolongation. Furthermore, preclinical juvenile rat studies demonstrated persistent adverse effects on bone density and locomotor activity. Off-label pediatric pharmacokinetic trials for vorinostat also revealed linear PK matching adult profiles, with identical dose-limiting toxicities including bone marrow depression and QT-prolongation. The class toxicity of the hydroxamate undoubtedly persists in pediatric populations. [1][2][3][4]

2. Failed Hydroxamic-Acid Drugs: Specific Toxicity Signals

The development of hydroxamic acids outside of oncology has been characterized by late-stage, catastrophic clinical failures, primarily due to off-target metalloenzyme inhibition.

Matrix Metalloproteinase (MMP) Inhibitors:

The most notorious failures of hydroxamic acids occurred during the development of broad-spectrum MMP inhibitors (including marimastat, batimastat, and prinomastat) in the late 1990s and early 2000s.

LpxC Inhibitors:

LpxC is a zinc-dependent deacetylase essential for Gram-negative bacterial lipid A biosynthesis. Numerous pharmaceutical programs pursued hydroxamate-based LpxC inhibitors, most notably ACHN-975 (Achaogen) and PF-04753299 (Pfizer).

3. Class-Wide Hydroxamic-Acid Liabilities to Flag

Based on the cumulative data, the following specific mechanisms represent extreme systemic risks for the 2-amino-quinoline-3-hydroxamate lead:

Hydroxamic-Acid Class Tox Profile

Signal	Evidence Strength	Drugs Affected	Mitigation Strategy
Cardiovascular (Hypotension & QTc Prolongation)	High (FDA Boxed Warnings, Phase 1 trial halts)	Panobinostat, Vorinostat, Givinostat, ACHN-975	Restrict to localized intratympanic delivery; perform early in vivo MAP telemetry.
Musculoskeletal Syndrome (MSS)	High (Phase 2/3 clinical failures)	Marimastat, Batimastat, Prinomastat	Screen lead against ADAM17 and MMP-1; structurally modify the ZBG to reduce promiscuous zinc chelation.
Genotoxicity (Ames + / Chromosomal aberration)	High (Class-wide regulatory warnings)	Belinostat, Panobinostat, Vorinostat	Block Lossen rearrangement via steric hindrance; evaluate hydroxylamine release rates in plasma stability assays.
GI Toxicity & Thrombocytopenia	High (Dose-limiting in all approved agents)	All approved HDAC inhibitors (Vorinostat, Panobinostat, Belinostat, Givinostat)	Avoid systemic oral administration; assess off-target HDAC4 and HDAC3 inhibition profiles.

Part C — 2-Amino-Quinoline Class Toxicity

The 2-amino-quinoline backbone features an extended, nitrogen-containing aromatic pi-system that introduces its own distinct toxicological signature, entirely separate from the hydroxamate head.

Ophthalmic Toxicity (Retinopathy):

While the classic antimalarial drugs chloroquine and hydroxychloroquine are 4-amino-quinolines, the 2-amino-quinoline chemotype shares a highly similar conjugated planar structure. Aminoquinolines have a profound biochemical affinity for melanin. Upon systemic administration, the drug preferentially binds to melanin biopolymers in the retinal pigment epithelium (RPE), leading to extreme, localized drug accumulation. Over time, this direct toxicity causes the destruction of surrounding photoreceptor cells, manifesting as a “bull’s eye” maculopathy, vortex keratopathy, and irreversible vision loss. Any systemically administered quinoline must be rigorously screened for retinal accumulation. [1][2][3][4][5]

Photosensitivity:

The extended aromatic pi-system of the quinoline ring readily absorbs ultraviolet and visible light radiation. Upon photoexcitation in the skin, the molecule converts to a triplet state, generating reactive oxygen species (ROS) and singlet oxygen. This oxidative stress triggers severe phototoxicity and photoallergy, presenting as extreme erythema, blistering, and hyperpigmentation upon sun exposure. [1][2][3][4][5]

Cardiotoxicity (hERG Channel Blockade):

The 2-amino-quinoline structure is an established pharmacophore for binding the human ether-à-go-go-related gene (hERG) potassium channel (Kv11.1). Blockade of the rapid delayed rectifier potassium current () during phase 3 of the cardiac action potential leads to delayed repolarization, manifesting as QT interval prolongation, and culminating in fatal ventricular arrhythmias such as Torsades de Pointes. When combined with the hypotensive properties of the hydroxamate, the cardiovascular risk of the lead molecule is compounded exponentially. [1][2][3][4][5]

Hepatotoxicity and CYP Interactions:

Quinoline derivatives are frequently associated with hepatic stress, often acting as competitive inhibitors or inducers of Cytochrome P450 enzymes (specifically CYP3A4 and CYP2D6), which can lead to severe drug-drug interactions. Additionally, chronic exposure to specific aminoquinolines (e.g., IQ) has been linked to focal myocardial necrosis and hepatocarcinogenesis in primate models. [1][2][3][4][5]

2-Amino-Quinoline Tox Profile

Signal	Evidence Strength	Drugs Affected	Mitigation Strategy
Ophthalmic Retinopathy	High (established clinical pathology)	Chloroquine, Hydroxychloroquine, Quinoline derivatives	Monitor OCT/ffERG in animal models; avoid chronic systemic dosing.
Photosensitivity	High (mechanistic chemical property)	General extended pi-system quinolines	Instruct patients on UV avoidance; structurally disrupt full aromaticity.
Cardiotoxicity (hERG blockade / QTc)	High (established pharmacophore)	Aminoquinolines, various kinase inhibitors	Perform automated patch-clamp electrophysiology on human Kv11.1 early in development.

Part D — Adamantyl-Amine Class Signals

The incorporation of a bulky, highly lipophilic, and rigid tricyclic adamantyl cage at the C2-amine tail introduces specific pharmacodynamic and pharmacokinetic properties. The adamantane motif is heavily utilized to force molecules into lipophilic binding pockets, prolong half-life, and improve blood-brain barrier (BBB) penetration. [1][2]

CNS Adverse Events:

The adamantyl-amine moiety is the primary pharmacophore of the antiviral and neuroprotective drugs amantadine and memantine. The rigid cage physically occludes the ion channel pore of the N-methyl-D-aspartate (NMDA) receptor in the central nervous system. If the lead compound is systemically bioavailable and crosses the BBB (facilitated by the highly lipophilic adamantyl tail), it is highly likely to exert off-target NMDA receptor antagonism, leading to neurological side effects including dizziness, confusion, hallucinations, and agitation. [1][2]

Dipeptidyl-Peptidase 4 (DPP-4) Inhibition and GI Signals:

The adamantyl structure is a core component of the antidiabetic drugs saxagliptin and vildagliptin. In these molecules, the adamantane moiety serves as a hydrophobic anchor, occupying the S1 pocket of the DPP-4 serine protease. Inhibition of DPP-4 affects glucose homeostasis by extending the half-life of incretin hormones (GLP-1). If the lead compound exhibits off-target DPP-4 inhibition, it could trigger unexpected hypoglycemic events, gastrointestinal distress, and immunological suppression (as CD26/DPP-4 is involved in T-cell function). Furthermore, vildagliptin has been recently associated with severe dermatological reactions, including bullous pemphigoid. [1][2]

Adamantyl Tox Profile

Signal	Evidence Strength	Drugs Affected	Mitigation Strategy
CNS Toxicity (NMDA receptor antagonism)	High (direct pharmacophore overlap)	Memantine, Amantadine, Rimantadine	Screen compound against NMDA channel binding; restrict systemic distribution to prevent BBB crossing.
Endocrine/GI Disruption (DPP-4 inhibition)	Medium (steric S1 pocket anchoring)	Saxagliptin, Vildagliptin	Include DPP-4 enzymatic inhibition assays in secondary pharmacological profiling.

Part E — Combined SAR-Toxicity Prediction and Recommendations

The culmination of the 2-amino-quinoline-3-hydroxamate core with an adamantyl-amine tail yields a molecule fraught with high systemic risks, yet presenting a potentially viable profile for intratympanic application. Standard in silico ADMET-AI panels relying on basic physicochemical parameters will accurately flag logP or topological polar surface area (TPSA), but will critically fail to predict the complex, target-mediated enzymatic interactions inherent to this specific chemotype (e.g., MSS via ADAM17, or retinopathy via melanin binding).

Top 5 Specific Tox Liabilities for Preclinical Wet-Lab Screening

The preclinical wet-lab pipeline must explicitly be structured to test the following hidden liabilities prior to advancing to non-human primate (NHP) or clinical stages:

1. Ames Mutagenicity via Hydroxylamine Cleavage:

Standard genotoxicity screens might return false negatives if the metabolic activation step (Lossen rearrangement or esterase cleavage) is not properly simulated. Actionable Screen: Conduct Ames fluctuation assays with and without S9 hepatic fraction metabolic activation. Quantify the rate of generation in human plasma and liver microsomes over 90 minutes via LC-MS to determine plasma stability.

2. hERG Blockade and Cardiovascular Hypotension:

This candidate carries a compounded risk: the 2-amino-quinoline core is primed to block hERG, while the hydroxamate will induce transient hypotension independently. Actionable Screen: Perform automated patch-clamp electrophysiology on human Kv11.1 (hERG) channels. Concurrently, perform in vivo radiotelemetry in rat or dog models to specifically monitor for drops in mean arterial pressure (MAP) independent of tachycardia.

3. Melanin Binding and Retinopathy:

The aminoquinoline scaffold will accumulate in the retinal pigment epithelium, destroying photoreceptors over time. Actionable Screen: Perform an in vitro melanin binding assay. If systemic (oral) delivery is pursued, mandate optical coherence tomography (OCT) and full-field electroretinography (ffERG) during chronic in vivo rodent toxicology studies to detect early inner retinal thinning.

4. Promiscuous Metalloenzyme Inhibition (ADAM17 / MMP-1):

The hydroxamate will aggressively bind off-target zinc metalloproteases, threatening severe joint fibrosis (Musculoskeletal Syndrome). Actionable Screen: Run an in vitro enzymatic selectivity panel against ADAM17, MMP-1, MMP-2, MMP-9, and MMP-13. If the inhibitory activity () against ADAM17 or MMP-1 is in the nanomolar range, the compound carries an extreme risk of MSS upon systemic exposure.

5. NMDA and DPP-4 Off-Target Engagement:

The rigid adamantyl tail guarantees the compound will explore lipophilic pockets native to the CNS and gastrointestinal regulators. Actionable Screen: Include NMDA receptor (competitive and non-competitive pore binding) and DPP-4 enzymatic inhibition fluorescence assays in the secondary pharmacological profiling panel.

Design-Around Suggestions & Structural Optimization

Given the severe systemic toxicities and the necessity to maintain FTO by avoiding Frequency Therapeutics’ IP regarding HDAC inhibition in the inner ear, the structure requires optimization. If intratympanic (local) delivery is exclusively utilized, the systemic risks (MSS, hERG, Retinopathy) are drastically minimized, though local cellular genotoxicity and target-site inflammation remain a concern. If oral (systemic) delivery is pursued, the current structure is functionally non-viable without profound modification.

To preserve the in silico scores (charge, logP, rigid geometry) while clearing FTO and abolishing toxicity, the following specific modifications are recommended:

• Replacing the Hydroxamate ZBG (Mitigating Mutagenicity and FTO):

To abolish the generation of mutagenic hydroxylamine, prevent the Lossen rearrangement, avoid the severe cardiovascular hypotension associated with hydroxamates, and distance the molecule from HDAC-inhibitor IP, the –C(=O)NHOH group must be replaced.

• Suggestion 1: 2-(1S-hydroxymethyl)-imidazole or 1,2,4-triazole. These non-hydroxamate zinc-binding moieties mimic the bidentate chelation geometry, preserving the hydrogen-bond donor/acceptor dynamics required for target engagement, but are completely metabolically stable and Ames-negative. This modification successfully rescued the LpxC inhibitor class from cardiovascular toxicity (e.g., TP 0586532). [1]

• Suggestion 2: Carbamoyl phosphonate. This moiety provides strong zinc chelation but carries a net negative charge at physiological pH, restricting cell penetration. If the target glycoprotein (stereocilin) is extracellular, this modification prevents the drug from entering the cell, entirely circumventing intracellular HDAC inhibition, DNA damage, and NMDA receptor crossing. [1]

• Modifying the 2-Amino-Quinoline Core (Mitigating Retinopathy and Photosensitivity):

The extended planar pi-system causes UV photoexcitation and massive melanin binding.

• Suggestion: Saturate the quinoline ring to a tetrahydroquinoline or replace it with a 2-amino-indanone scaffold. Disruption of the full aromaticity reduces the pi-stacking interactions necessary for melanin affinity and raises the HOMO-LUMO gap, drastically reducing UV absorption and phototoxicity, without significantly altering the relative vectors of the C3-head and C2-tail. [1]

• Altering the Adamantyl Tail (Mitigating NMDA/DPP-4 Affinities):

The pure hydrocarbon nature of adamantane drives its promiscuous binding into deep hydrophobic pockets.

• Suggestion: Substitute the adamantyl cage with a 3-hydroxy-adamantyl or 3-fluoro-adamantyl group. The introduction of a single polar or highly electronegative atom onto the cage preserves the exact spatial geometry and steric bulk, but drastically shifts the electrostatic potential map. This simple addition prevents the deep burial of the tail into strictly hydrophobic pockets (like the NMDA pore or the DPP-4 S1 pocket), reducing off-target effects while maintaining target pharmacochaperone geometry.

By implementing these structural pivots, the development program can legally circumvent existing IP, eliminate the fatal toxicological flaws of the precursor classes, and secure a viable path toward a first-in-class pharmacochaperone for DFNB16 hearing loss.

1. https://patents.google.com/patent/US3446809A/en (US3446809A - Process for the preparation of 2-amino-3-hydroxyquinoxalines - Google Patents)

2. https://patents.google.com/patent/US3446809A/en (US3446809A - Process for the preparation of 2-amino-3-hydroxyquinoxalines - Google Patents)

3. https://www.ambeed.com/products/31407-28-0.html (31407-28-0 | 2-Aminoquinoline-3-carboxamide | Amides | Ambeed.com)

4. https://www.researchgate.net/publication/237983453_ChemInform_Abstract_A_New_Synthetic_Approach_to_Functionalize_Pyrimido45-bquinoline-241H3H-diones_via_a_Three-Component_One-Pot_Reaction (ChemInform Abstract: A New Synthetic Approach to Functionalize Pyrimido[4,5-b]quinoline-2,4(1H,3H)-diones via a Three-Component One-Pot Reaction | Request PDF - ResearchGate)

5. https://patentimages.storage.googleapis.com/03/45/16/447653c187277f/US8680139.pdf (United States Patent - Googleapis.com)

6. https://pmc.ncbi.nlm.nih.gov/articles/PMC12521396/ (Adverse drug reaction profiles of histone deacetylase inhibitors - PMC)

7. https://pmc.ncbi.nlm.nih.gov/articles/PMC4466128/ (New strategies for targeting matrix metalloproteinases - PMC - NIH)